glp 1 economist The appetite for weight-loss drugs, known as GLP-1 agonists, has been insatiable since they hit the market a decade ago. As pharmaceutical firms elbow each other for a slice of the pie Competition will make weight-loss drugs

D.LuM.ArdayfioP.SparksJ.et al

10.1001/jama.2018.18269 [Epub ahead of print]

Alissa: For employer groups who are considering covering weight loss, its important to note that while it can initially increase drug spend, it can have a lot of favorable impacts down the line to reduce medical spend

Healthcare professionals emphasize that even brief exposure to extreme temperatures raises concerns about whether semaglutide does expire after 28 days and can compromise its potency

Many commercial plans now cover GLP-1 drugs for obesity, but prior authorization requirements, step-therapy mandates, and cost-sharing can still create significant barriers

Yu F, Zhang Y, Yang C, Li F, Qiu B, Ding W